ArticleNeuroimage. Reports2026
Neural and biomarker correlates of the Parkinson's Disease-Cognitive Rating Scale in Huntington's disease.
Article in Neuroimage. Reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive decline is a core feature of Huntington's disease (HD), often preceding motor symptoms and progressing with disease severity. While several neuropsychological tests track cognitive changes, few studies have examined the biological correlates of brief screening tools adapted for HD. Objectives: This study investigates the neuroanatomical and fluid biomarker correlates of performance on the Parkinson's Disease-Cognitive Rating Scale (PD-CRS), aiming to validate it as a clinically and biologically grounded tool for cognitive assessment in HD. Methods: Fifty-two symptomatic gene-expansion carriers (CAG >39) underwent cognitive (PD-CRS), motor (UHDRS), and behavioral (PBA) assessments. Plasma neurofilament light chain (NfL) levels were measured via Simoa as a marker of neurodegeneration. Voxel-based morphometry (VBM) was used to identify gray matter volume (GMV) correlates of PD-CRS scores. Linear regressions evaluated relationships among PD-CRS, GMV, and NfL, including subdomain-level and stage-stratified analyses based on HD-ISS classification. Results: PD-CRS scores were significantly associated with GMV in frontostriatal, paralimbic, parietal, and occipital regions. NfL levels correlated with both cognitive scores and GMV in key regions, supporting their value as biomarkers of neurodegeneration. Subdomain analyses revealed region-specific associations (e.g., visuospatial tasks with posterior cortices, fluency with striatum). Perseveration, motor severity, and education predicted PD-CRS performance (adjusted R Conclussions: The PD-CRS reflects biologically meaningful aspects of cognitive dysfunction in HD, with robust associations to structural and molecular disease markers. These findings support its use as a practical and sensitive tool for clinical and research applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.